DPACE-based chemotherapy in the era of myeloma novel agents: A UK multicentre study

Eur J Haematol. 2020 Aug;105(2):231-233. doi: 10.1111/ejh.13422. Epub 2020 Apr 21.

Authors

Affiliations

¹ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
³ Department of Haematology, Royal Wolverhampton NHS Trust, Wolverhampton, UK.
⁴ Department of Haematology, Wexham Park Hospital, Slough, UK.
⁵ University of Wolverhampton, Wolverhampton, UK.

PMID: 32268442
DOI: 10.1111/ejh.13422

No abstract available

Keywords: DPACE; DTPACE; VRDPACE; VTDPACE; efficacy; myeloma; survival.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / administration & dosage
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Etoposide / administration & dosage
Humans
Multicenter Studies as Topic
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Prognosis
Treatment Outcome
United Kingdom

Substances

Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin